Dashboard
Watchlists
Collections
Events
Tools
SIGN UP
SIGN IN
bearish
Yunkang Group
Watchlist
Pre-IPO Yunkang Group - Lack of New Growth Point
The COVID-19 business isn't enough to support Yunkang's future development. It also lacks new growth points. It is recommended to calculate its future valuation by excluding COVID-19 related projects.
Equity Capital Markets
220 Views
01 Mar 2022 08:47
SUMMARY
(Sign Up to Access)
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
Unlimited Research Summaries
Personalised Alerts
Custom Watchlists
Company Analytics & News
Events & Webinars
Trusted by:
SMARTKARMA PREVIEW PASS
Sign Up with LinkedIn
or
First Name
Last name
Email
Sign Up with Email
By signing up, you agree to our
Terms of Use
and
Privacy Policy
.
Trusted by:
Already have an account?
Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
China
Health Care
Equity Bottom-Up
Thematic (Sector/Industry)
View Full Profile
Price Chart
(Sign Up to Access)
Insight Stream
H&H (1112): Difficult Period?
07 May 2022
Health And Happiness (H&H) (1112.HK) - High Bankruptcy Risk Together with Gloomy Prospects
06 May 2022
New Horizon Health (6606.HK) - Far from Complete Reversal
02 Mar 2022
Pre-IPO Yunkang Group - Lack of New Growth Point
01 Mar 2022
WuXi AppTec (2359.HK/603259.CH)- Interesting Points to Ponder Behind 2021 Preliminary Financial Data
23 Feb 2022
Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
10 Feb 2022
Oral COVID-19 Antivirals and the Impact on China
28 Dec 2021
Top
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.17.1
x